J. Wallach

Robert T. Thibault, Mallory C. Kidwell, J. Ioannidis, 2021, Perspectives on psychological science : a journal of the Association for Psychological Science.

Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs

C. Gross, J. Wallach, J. Ross, 2021, JAMA network open.

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors

J. Wallach, J. Ross, A. Zhang, 2021, JAMA network open.

Beyond genomics: understanding exposotypes through metabolomics

Caroline H. Johnson, J. Ioannidis, V. Vasiliou, 2018, Human Genomics.

Assessment of transparency indicators across the biomedical literature: How open is open?

Kevin W. Boyack, John P. A. Ioannidis, Nico Riedel, 2020, bioRxiv.

Beyond genomics: understanding exposotypes through metabolomics

Caroline H. Johnson, J. Ioannidis, V. Vasiliou, 2018, Human Genomics.

Biomedical journal speed and efficiency: a cross-sectional pilot survey of author experiences

H. Krumholz, J. Wallach, J. Ross, 2018, Research Integrity and Peer Review.

Evaluation of Evidence of Statistical Support and Corroboration of Subgroup Claims in Randomized Clinical Trials

Kristin L. Sainani, J. Ioannidis, E. Steyerberg, 2017, JAMA internal medicine.

Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis

Lisa M. Schwartz, J. Wallach, J. Ross, 2018, Journal of General Internal Medicine.

Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation

J. Wallach, J. Ross, J. Puthumana, 2018, JAMA.

The US Food and Drug Administration’s expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements

J. Wallach, J. Ross, H. Naci, 2018, Clinical trials.

Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study

H. Krumholz, J. Wallach, J. Ross, 2018, BMC Medicine.

Characterizing Patient‐Centered Postoperative Recovery After Adult Cardiac Surgery: A Systematic Review

H. Krumholz, S. Chaudhry, J. Wallach, 2019, Journal of the American Heart Association.

Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics

C. Gross, J. Wallach, J. Ross, 2021, JAMA network open.

Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses

J. Ioannidis, E. Steyerberg, Patrick Sullivan, 2016, British Medical Journal.

Gabapentin Approvals, Off-Label Use, and Lessons for Postmarketing Evaluation Efforts.

J. Wallach, J. Ross, 2018, JAMA.

Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study

J. Wallach, Reshma Ramachandran, Joseph S. Ross, 2022, BMJ.

Transparency of Regulatory Data across the European Medicines Agency, Health Canada, and US Food and Drug Administration

J. Wallach, J. Ross, M. McCarthy, 2021, Journal of Law, Medicine & Ethics.

An empirical assessment of transparency and reproducibility-related research practices in the social sciences (2014-2017)

Mallory C. Kidwell, J. Ioannidis, T. Hardwicke, 2019 .

Consistency between trials presented at conferences, their subsequent publications and press releases

J. Wallach, A. Rowhani-Farid, Kyungwan Hong, 2022, BMJ Evidence-Based Medicine.

Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment

P. Noseworthy, J. Wallach, E. Polley, 2021, JAMA network open.

Comparison of Clinical Study Results Reported in medRxiv Preprints vs Peer-reviewed Journal Articles

J. Wallach, Joseph S. Ross, V. Khetpal, 2022, JAMA network open.

Assessment of Concordance and Discordance Among Clinical Studies Posted as Preprints and Subsequently Published in High-Impact Journals

H. Krumholz, J. Wallach, J. Ross, 2021, JAMA network open.

Publishing at any cost: a cross-sectional study of the amount that medical researchers spend on open access publishing each year

J. Wallach, J. Ross, K. Nyhan, 2021, BMJ Open.

Publishing at any cost: a cross-sectional study of the amount that medical researchers spend on open-access publishing each year

J. Wallach, J. Ross, K. Nyhan, 2020, medRxiv.

Not Reporting Results of a Clinical Trial Is Academic Misconduct

Harlan Krumholz, H. Krumholz, J. Wallach, 2019, Annals of Internal Medicine.

Adherence to the International Committee of Medical Journal Editors’ (ICMJE) prospective registration policy and implications for outcome integrity: a cross-sectional analysis of trials published in high-impact specialty society journals

Rafael Dal-Ré, Joshua D. Wallach, Gregg Gonsalves, 2018, Trials.

Characteristics of Retracted Research Articles About COVID-19 vs Other Topics

J. Wallach, I. Oransky, Alison Abritis, 2022, JAMA network open.

Research, regulatory, and clinical decision-making: the importance of scientific integrity.

Joseph S Ross, Joshua D Wallach, Gregg S Gonsalves, 2018, Journal of clinical epidemiology.

Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies

J. Wallach, J. Ross, S. Dhruva, 2019, Journal of General Internal Medicine.

Characteristics of available studies and dissemination of research using major clinical data sharing platforms

C. Gross, J. Wallach, J. Ross, 2021, Clinical trials.

Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018

J. Wallach, J. Ross, Reshma Ramachandran, 2021, JAMA network open.

On-Label and Off-Label Clinical Studies of FDA-Approved Ophthalmic Therapeutics.

C. Regillo, J. Wallach, J. Ross, 2020, Ophthalmology.

Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015

J. Wallach, J. Ross, A. Zhang, 2020, JAMA network open.

Systematic overview of Freedom of Information Act requests to the Department of Health and Human Services from 2008 to 2017

P. Lurie, J. Wallach, J. Ross, 2019, Research integrity and peer review.

Biomedical journal speed and efficiency: a cross-sectional pilot survey of author experiences

H. Krumholz, J. Wallach, J. Ross, 2018, Research integrity and peer review.

US Food and Drug Administration regulatory reviewer disagreements and postmarket safety actions among new therapeutics

J. Wallach, Joseph Ross, M. Herder, 2023, BMJ Evidence-Based Medicine.

Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval

J. Wallach, J. Ross, N. Shah, 2021, JAMA network open.

Assessing the use of observational methods and real-world data to emulate ongoing randomized controlled trials

P. Noseworthy, J. Wallach, J. Herrin, 2023, Clinical trials.

Comparative effectiveness of second line glucose lowering drug treatments using real world data: emulation of a target trial

J. Wallach, J. Herrin, R. McCoy, 2023, BMJ medicine.

Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses

J. Wallach, H. Krumholz, A. Zhang, 2021, BMJ.

Prevalence and significance of race and ethnicity subgroup analyses in Cochrane intervention reviews

J. Ioannidis, V. Vasiliou, J. Wallach, 2019, Clinical trials.

Estimating the prevalence of transparency and reproducibility-related research practices in psychology (2014-2017)

Robert T. Thibault, Mallory C. Kidwell, J. Ioannidis, 2020 .

Association of health benefits and harms of Christmas dessert ingredients in recipes from The Great British Bake Off: umbrella review of umbrella reviews of meta-analyses of observational studies

J. Wallach, Reshma Ramachandran, Joseph S Ross, 2023, BMJ.

Consideration of confounding in epidemiologic studies assessing alcohol consumption on the risk of breast cancer: A brief report.

J. Wallach, Lingzhi Chu, 2020, Chemico-biological interactions.

Autoimmune diseases and risk of non-Hodgkin lymphoma: A Mendelian randomisation study

J. Wallach, T. Rogne, Xiaomei Ma, 2024, medRxiv.

Feasibility of using real-world data to emulate substance use disorder clinical trials: a cross-sectional study

J. Wallach, Reshma Ramachandran, G. Janda, 2024, BMC medical research methodology.

Premarket Pivotal Trial End Points and Postmarketing Requirements for FDA Breakthrough Therapies

J. Wallach, Reshma Ramachandran, M. Mooghali, 2024, JAMA network open.

Associations Between Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments.

J. Wallach, O. Ciani, Reshma Ramachandran, 2024, JAMA.

Breakthrough Therapy Designation for New Drugs-Reply.

J. Wallach, J. Ross, Jeremy Puthumana, 2018, JAMA.

Surrogate Markers and Clinical Outcomes-Reply.

J. Wallach, Reshma Ramachandran, Joseph S Ross, 2024, JAMA.

Evaluation of confounding in epidemiologic studies assessing alcohol consumption on the risk of ischemic heart disease: a cross-sectional analysis

J. Wallach, 2021 .